EFTReFFECTOR Therapeutics, Inc.

Nasdaq effector.com


$ 1.69 $ 0.03 (1.81 %)    

Thursday, 30-May-2024 13:48:42 EDT
QQQ $ 454.82 $ -4.95 (-1.09 %)
DIA $ 398.57 $ -3.15 (-0.82 %)
SPY $ 530.36 $ -3.68 (-0.7 %)
TLT $ 91.26 $ 0.84 (0.94 %)
GLD $ 225.37 $ 0.38 (0.18 %)
$ 1.7
$ 1.69
$ 0.00 x 0
$ 0.00 x 0
$ 1.69 - $ 1.69
$ 1.60 - $ 37.00
74,695
na
6.78M
$ 1.56
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-26-2024 12-31-2023 10-K
3 11-13-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 03-08-2023 12-31-2022 10-K
7 11-07-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 03-16-2022 12-31-2021 10-K
11 11-08-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 06-03-2021 03-31-2021 10-Q
14 03-29-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 effector-therapeutics-q1-2024-gaap-eps-216-beats-217-estimate-reports-cash-runway-into-q1-of-2025

eFFECTOR Therapeutics (NASDAQ:EFTR) reported quarterly losses of $(2.16) per share which beat the analyst consensus estimate of...

 dow-dips-over-200-points-rpm-international-shares-fall-after-q3-results

U.S. stocks turned lower toward the end of trading, with the Dow Jones index falling more than 200 points on Thursday. The Dow...

 why-staar-surgical-shares-are-trading-higher-by-around-13-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of STAAR Surgical Company (NASDAQ: STAA) rose sharply during Thursday’s session after the company issued strong prelimi...

 nasdaq-surges-1-conagra-brands-posts-upbeat-earnings

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 150 points on Thursday. The Dow ...

 cancer-focused-effector-therapeutics-shelves-development-of-lung-cancer-candidate-after-disappointing-data

eFFECTOR Therapeutics unveils Phase 2 KICKSTART trial results for tomivosertib with Keytruda in NSCLC patients. Tomivosertib sh...

 dow-jumps-over-100-points-us-jobless-claims-increase-to-221000

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 100 points on Thursday. Following the marke...

 effector-therapeutics-announces-topline-results-of-phase-2-kickstart-trial-of-tomivosertib-combined-with-pembrolizumab-in-non-small-cell-lung-cancer

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) fo...

 hc-wainwright--co-reiterates-buy-on-effector-therapeutics-maintains-24-price-target

HC Wainwright & Co. analyst Robert Burns reiterates eFFECTOR Therapeutics (NASDAQ:EFTR) with a Buy and maintains $24 pri...

 effector-therapeutics-cash-cash-equivalents-and-short-term-investments-totaling-184m-as-of-december-31-2023-anticipates-that-it-will-be-sufficient-to-fund-operations-into-q1-of-2025

Fourth Quarter and Full Year 2023 Financial ResultsCash Position and Guidance: The company had cash, cash equivalents, and shor...

 effector-therapeutics-q4-eps-342-misses-165-estimate

eFFECTOR Therapeutics (NASDAQ:EFTR) reported quarterly losses of $(3.42) per share which missed the analyst consensus estimate ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION